{"url_path":"/sec/cldi/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-033594-index.html","accession_number":"0001493152-26-033594","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-033594-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":110,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit**\n** **\n**Exhibit\nDescription**\n\n10.1\n \n[Lease Agreement, dated July 10, 2026, by and between BP3-SD4 5580 Morehouse Drive LLC and Calidi Biotherapeutics, Inc.](ex10-1.htm)\n\n10.2\n \n[Lease Termination Agreement, dated July 10, 2026, by and between 4475 Executive Drive LLC and Calidi Biotherapeutics, Inc.](ex10-2.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**CALIDI BIOTHERAPEUTICS, INC.**\n\n \n \n \n\nDated: July 16, 2026\n \n \n\n \nBy:\n*/s/ Andrew\nJackson*\n\n \nName:\nAndrew Jackson\n\n \nTitle:\nChief Financial Officer"}